Companion Animal Drugs Market by Product Type, By Animal Type, By Route of Administration, Distribution Channel, and Region Forecast 2019-2030
Companion Animal Drugs Market size was valued at US$ 12 Bn in 2023 and is projected to reach US$ 19.81 Bn by 2030 poised to grow at a significant CAGR of 6.3% from 2024-2030. owing to rising human and companion animal by means of adoption across the globe. This report studies market dynamics elaborately to identify the current trends & drivers, future opportunities and possible challenges to the key stakeholders operating in the market. In addition, the companion animal pharmaceutical market report includes animal demographics; regulatory scenario, and competition analysis with vividly illustrated the competition dashboard to assess the market competition.
Moreover, PBI analyzed the market to better equip clients with possible investment opportunities across the regions (Regional Investment Hot-Spots) and market unmet needs (Product Opportunities). Key stakeholders of the market report include suppliers, manufacturers, marketers, policymakers, and veterinary healthcare service providers engaged in manufacturing and supply of companion animal drug products. Several respondents and pet owners revealed that pet expenditure is increasingly becoming an integral part of their monthly expenditure and companion animals are part of several families across the developed and developing economies. Moreover, rising interactions between pets and human beings prompting the caregivers and pet owners to adopt better healthcare services to the companion animals is projected to drive market revenue growth over the forecast period.
Study Period
2024-2030Base Year
2023CAGR
6.3%Largest Market
North AmericaFastest Growing Market
Europe
Rising Pet companionship to human beings expected to drive the market over the forecast period. Companion animals have been trusted for their companionship to the human throughout the history and keeping the companion animals healthy is a top priority for caregivers everywhere in the world, which is expected to drive the companion animal pharmaceutical market over six years forecast period. Moreover, several studies on human and companion animals™ interactions showed that association with companion animals results in positive health benefits. Therefore, it is essential to veterinarians and caregivers to give utmost attention to companion animal health as companion animals are the primary source of zoonotic diseases spread to humans and vice versa, this is expected to create significant market demand for companion animal drugs over the forecast period.
U.S. market dominated the market with the largest market share in the North America market with moderate growth rate. Europe companion animal drugs market holds a significant share in the global market and projected to grow at a significant growth over the forecast period.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market CAGR |
6.3% |
|
By Product Type |
|
|
By Animal Type |
|
|
By Route of Administration |
|
|
By Distribution Channel |
|
|
By Region |
|
Download Free Sample Report
Companion animal drugs market size was valued at US$ 12 Bn in 2023 and is set to reach US$ 19.81 Bn by 2030 growing at a CAGR of 6.3% from 2024-2030.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Europe is the fastest-growing for the market.
| 1.Executive Summary |
| 2.Global Companion Animal Drugs Market Introduction |
| 2.1.Global Companion Animal Drugs Market - Taxonomy |
| 2.2.Global Companion Animal Drugs Market - Definitions |
| 2.2.1.Product Type |
| 2.2.2.Animal Type |
| 2.2.3.Route of Administration |
| 2.2.4.Distribution Channel |
| 2.2.5.Region |
| 3.Global Companion Animal Drugs Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Companion Animal Drugs Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Companion Animal Drugs Market By Product Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Antimicrobials |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Ectoparasiticides |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Endoparacitides |
| 5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Endectoparaciticides |
| 5.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Anti-inflammatory Drugs |
| 5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Anti-Obesity Drugs |
| 5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Behavioral Products |
| 5.7.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.7.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Biologic Drugs |
| 5.8.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.8.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Others |
| 5.9.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.9.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 6.Global Companion Animal Drugs Market By Animal Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Feline |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Canine |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Equine |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Companion Animal Drugs Market By Route of Administration, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. Oral |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Parenteral |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Topical |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Others |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 8.Global Companion Animal Drugs Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Veterinary Pharmacies |
| 8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. Veterinary Hospitals |
| 8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Veterinary Clinics |
| 8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. E-Commerce |
| 8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 9.Global Companion Animal Drugs Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia Pacific (APAC) |
| 9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Middle East and Africa (MEA) |
| 9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Latin America |
| 9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 10.North America Companion Animal Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Product Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Antimicrobials |
| 10.1.2.Ectoparasiticides |
| 10.1.3.Endoparacitides |
| 10.1.4.Endectoparaciticides |
| 10.1.5.Anti-inflammatory Drugs |
| 10.1.6.Anti-Obesity Drugs |
| 10.1.7.Behavioral Products |
| 10.1.8.Biologic Drugs |
| 10.1.9.Others |
| 10.2. Animal Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Feline |
| 10.2.2.Canine |
| 10.2.3.Equine |
| 10.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.Oral |
| 10.3.2.Parenteral |
| 10.3.3.Topical |
| 10.3.4.Others |
| 10.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.4.1.Veterinary Pharmacies |
| 10.4.2.Veterinary Hospitals |
| 10.4.3.Veterinary Clinics |
| 10.4.4.E-Commerce |
| 10.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.5.1.United States of America (USA) |
| 10.5.2.Canada |
| 11.Europe Companion Animal Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Antimicrobials |
| 11.1.2.Ectoparasiticides |
| 11.1.3.Endoparacitides |
| 11.1.4.Endectoparaciticides |
| 11.1.5.Anti-inflammatory Drugs |
| 11.1.6.Anti-Obesity Drugs |
| 11.1.7.Behavioral Products |
| 11.1.8.Biologic Drugs |
| 11.1.9.Others |
| 11.2. Animal Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Feline |
| 11.2.2.Canine |
| 11.2.3.Equine |
| 11.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.Oral |
| 11.3.2.Parenteral |
| 11.3.3.Topical |
| 11.3.4.Others |
| 11.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.4.1.Veterinary Pharmacies |
| 11.4.2.Veterinary Hospitals |
| 11.4.3.Veterinary Clinics |
| 11.4.4.E-Commerce |
| 11.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.5.1.Germany |
| 11.5.2.France |
| 11.5.3.Italy |
| 11.5.4.United Kingdom (UK) |
| 11.5.5.Spain |
| 11.5.6.Rest of EU |
| 11.5.7. |
| 12.Asia Pacific (APAC) Companion Animal Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Antimicrobials |
| 12.1.2.Ectoparasiticides |
| 12.1.3.Endoparacitides |
| 12.1.4.Endectoparaciticides |
| 12.1.5.Anti-inflammatory Drugs |
| 12.1.6.Anti-Obesity Drugs |
| 12.1.7.Behavioral Products |
| 12.1.8.Biologic Drugs |
| 12.1.9.Others |
| 12.2. Animal Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Feline |
| 12.2.2.Canine |
| 12.2.3.Equine |
| 12.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Oral |
| 12.3.2.Parenteral |
| 12.3.3.Topical |
| 12.3.4.Others |
| 12.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.4.1.Veterinary Pharmacies |
| 12.4.2.Veterinary Hospitals |
| 12.4.3.Veterinary Clinics |
| 12.4.4.E-Commerce |
| 12.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.5.1.China |
| 12.5.2.India |
| 12.5.3.Australia and New Zealand (ANZ) |
| 12.5.4.Japan |
| 12.5.5.Rest of APAC |
| 13.Middle East and Africa (MEA) Companion Animal Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 13.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1.Antimicrobials |
| 13.1.2.Ectoparasiticides |
| 13.1.3.Endoparacitides |
| 13.1.4.Endectoparaciticides |
| 13.1.5.Anti-inflammatory Drugs |
| 13.1.6.Anti-Obesity Drugs |
| 13.1.7.Behavioral Products |
| 13.1.8.Biologic Drugs |
| 13.1.9.Others |
| 13.2. Animal Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.2.1.Feline |
| 13.2.2.Canine |
| 13.2.3.Equine |
| 13.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.3.1.Oral |
| 13.3.2.Parenteral |
| 13.3.3.Topical |
| 13.3.4.Others |
| 13.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.4.1.Veterinary Pharmacies |
| 13.4.2.Veterinary Hospitals |
| 13.4.3.Veterinary Clinics |
| 13.4.4.E-Commerce |
| 13.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 13.5.1.GCC Countries |
| 13.5.2.South Africa |
| 13.5.3.Rest of MEA |
| 14.Latin America Companion Animal Drugs Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 14.1. Product Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1.Antimicrobials |
| 14.1.2.Ectoparasiticides |
| 14.1.3.Endoparacitides |
| 14.1.4.Endectoparaciticides |
| 14.1.5.Anti-inflammatory Drugs |
| 14.1.6.Anti-Obesity Drugs |
| 14.1.7.Behavioral Products |
| 14.1.8.Biologic Drugs |
| 14.1.9.Others |
| 14.2. Animal Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.2.1.Feline |
| 14.2.2.Canine |
| 14.2.3.Equine |
| 14.3. Route of Administration Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.3.1.Oral |
| 14.3.2.Parenteral |
| 14.3.3.Topical |
| 14.3.4.Others |
| 14.4. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.4.1.Veterinary Pharmacies |
| 14.4.2.Veterinary Hospitals |
| 14.4.3.Veterinary Clinics |
| 14.4.4.E-Commerce |
| 14.5. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 14.5.1.Brazil |
| 14.5.2.Mexico |
| 14.5.3.Rest of LA |
| 15. Competition Landscape |
| 15.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 15.2.1.Bayer AG (Germany) |
| 15.2.2.Boehringer Ingelheim GmbH (Germany) |
| 15.2.3.Ceva Santé Animale (France) |
| 15.2.4.Eli Lilly and Company (U.S) |
| 15.2.5.Hester biosciences (India) |
| 15.2.6.Merck & Co., Inc. (U.S) |
| 15.2.7.Va©toquinol S.A. (France) |
| 15.2.8.Virbac S.A. (France) |
| 15.2.9.Zoetis Inc. (U.S) |
| 15.2.10.Allscripts Healthcare Solutions Inc. (U.S) |
| 16. Research Methodology |
| 17. Appendix and Abbreviations |
Key Market Players
Author
Manoj Kumar is a postgraduate in Life Sciences with over seven years of dedicated experience in the fields of animal health and agriculture. His passion lies in unraveling the complexities of these domains through rigorous research and practical insights. Manoj Kumar’s journey has been marked by several key achievements: as a market analyst and competitive intelligence expert, he dissects data to provide actionable insights for global clients. Simultaneously, he champions animal healthcare, diagnosing ailments, and designing preventive care strategies. In the realm of agriculture, his focus on sustainable practices, emphasizing crop nutrition, soil health, and precision agriculture. His holistic approach and commitment to advancing science make him a respected figure in the ever-evolving landscape of life sciences.
Download Free Sample
